Effect of Topically Applied 0.5% Apraclonidine Versus 0.5% Timolol Maleate on Intraocular Pressure of Healthy Horses.
Authors: Ziadi Aida, Ozmaie Saeed, Asghari Ahmad, Rajaei Seyed Mehdi
Journal: Journal of equine veterinary science
Summary
# Editorial Summary: Apraclonidine versus Timolol for Equine Intraocular Pressure Management Elevated intraocular pressure (IOP) is a significant concern in equine ophthalmology, particularly in conditions like glaucoma, yet topical medication options remain limited in horses. Ziadi and colleagues compared two alpha-2 adrenergic and beta-blocker agents by administering single 0.2 mL doses of either 0.5% apraclonidine or 0.5% timolol maleate to one eye of 20 healthy thoroughbred mares, with contralateral eyes receiving artificial tears as control, and measuring IOP via rebound tonometry over 24 hours. Apraclonidine demonstrated clinically superior and more rapid pressure reduction, with statistically significant IOP decreases evident from 60 minutes onwards and sustained at 24 hours (P<0.001), whereas timolol only achieved significant reduction at the 24-hour timepoint (P=0.03). The alpha-2 agonist produced substantially greater mean IOP reduction compared to the beta-blocker across the observation period, suggesting apraclonidine may offer a more effective alternative for managing equine glaucoma or elevated IOP cases. Whilst these findings are promising, practitioners should note this was a single-dose study in healthy horses; further investigation into safety, tolerability, and efficacy in clinical disease states—particularly recurrent or chronic elevated pressure—remains essential before widespread adoption in practice.
Read the full abstract on PubMed
Practical Takeaways
- •Apraclonidine may be a more effective topical option than timolol for rapid IOP reduction in equine patients, with therapeutic effect beginning within one hour
- •Veterinarians treating horses with elevated IOP should consider apraclonidine as a viable alternative, pending further safety and efficacy studies in clinical disease
- •The sustained 24-hour IOP-lowering effect of apraclonidine suggests potential for convenient once-daily or twice-daily dosing protocols in equine ophthalmology
Key Findings
- •Topical 0.5% apraclonidine significantly reduced IOP starting at 60 minutes post-application and maintained reduction through 24 hours in treated eyes
- •Timolol maleate 0.5% only achieved statistically significant IOP reduction at 24 hours, with maximum reduction of 14.7% at 360 minutes
- •Apraclonidine produced more prominent IOP reduction compared to timolol in treated eyes across the observation period
- •Single dose topical apraclonidine was well-tolerated in healthy horses with no reported ocular side effects